FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to thermoformed pharmaceutical dosage form having a minimum tensile strength of 300 N; the above dosage form contains an opioid, a free physiologically acceptable carboxylic acid in an amount from 0.1 to 5.0 wt %, at total weight of the pharmaceutical dosage form and polyalkylene oxide having a minimum average molecular weight Mm of 500,000 g/mole. Carboxylic acid is specified in a group consisting of maleic acid, fumaric acid, glutaric acid, malonic acid and citric acid. The opioid is specified in a group consisting of oxymorphone, oxycodone, hydromorphone and their physiologically acceptable salts. The pharmaceutical dosage form can be packaged.
EFFECT: pharmaceutical dosage for according to the invention is characterised by the improved storage stability.
14 cl, 11 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| OXIDATION STABLE AND BREAKING RESISTANCE DOSAGE FORM | 2010 |
|
RU2567723C2 |
| DRUG FORM | 2009 |
|
RU2493830C2 |
| DESTRUCTION-RESISTANT DOSAGE FORM CONTAINING AN INORGANIC SALT | 2011 |
|
RU2604676C2 |
| DESTRUCTION-RESISTANT DOSAGE FORM CONTAINING ANIONIC POLYMER | 2011 |
|
RU2607499C2 |
| PROTECTED AGAINST UNADMINISTERED APPLICATION PERORAL MEDICATION FORM | 2005 |
|
RU2396944C2 |
| PHARMACEUTICAL PREPARATIVE FORM | 2004 |
|
RU2362560C2 |
| HOT-MELT EXTRUDED PHARMACEUTICAL DOSAGE FORM | 2010 |
|
RU2547555C2 |
| DOSAGE FORM PROTECTED FROM UNINTENDED USE AND CONTAINING (1R, 2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYLPROPYL)PHENOL | 2005 |
|
RU2393847C2 |
| PHARMACEUTICAL COMPOSITION, CONTAINING OPIOID ANTAGONIST FOR TREATMENT OF URINARY RETENTION | 2009 |
|
RU2478388C2 |
| TAPENTADOL FOR TREATMENT CAUSED BY OSTEOARTHROSIS | 2008 |
|
RU2473337C2 |
